The results obtained in preclinical systems as well as the first clinical trials suggest that local IL-2 immunotherapy may represent a novel approach to the treatment of some neoplasms. However, the experimental results should be confirmed and substantially extended before definitive conclusions can be drawn. We hope that the data and considerations discussed in this article will facilitate thoughts concerned with future clinical IL-2 trials and be instrumental in the optimization of IL-2 cancer immunotherapy.

Institute of Molecular Genetics Czechoslovak Academy of Sciences Prague

Zobrazit více v PubMed

Adler A, Stein JA, Kedar E, Naor D, Weiss DW (1984) Intralesional injection of interleukin-2-expanded autologous lymphocytes in melanoma and breast cancer patients: a pilot study. J Biol Response Mod 3:491 PubMed

Brandhuber BJ, Boone T, Kenney WC, McKay DB (1987) Three-dimensional structure of interleukin-2. Science 238:1707 PubMed

Bubeník J (1989a) Tumor inhibitory effects of regional interleukin 2 administration and the role of lymphokine-activated killer cells. In: Lotzová E, Herberman R (eds) Role of interleukin-2 activated killer cells in cancer. CRC, Boca Raton, Florida (in press)

Bubeník J (1989b) Local immunotherapy of cancer with interleukin 2. Immunol Lett 21:267 PubMed

Bubeník J, Indrová M (1987a) The antitumour efficacy of human recombinant interleukin 2: correlation between sensitivity of tumours to the cytolytic effect of LAK cells in vitro and their susceptibility to the IL-2 immunotherapy in vivo. Cancer Immunol Immunother 24:269 PubMed PMC

Bubeník J, Indrová M (1987b) Cancer immunotherapy using local interleukin-2 administration. Immunol Lett 16:305 PubMed

Bubeník J, Perlman P, Indrová M, Šímová J, Jandlová T, Neuwirt J (1983) Growth inhibition of an MC-induced mouse sarcoma by TCGF (IL-2)-containing preparations. Cancer Immunol Immunother 14:205 PubMed PMC

Bubeník J, Indrová M, Perlmann P, Berzins K, Mach O, Kraml J, Toulcová A (1985) Tumor-inhibitory effects of TCGF (IL-2)containing preparations. Cancer Immunol Immunother 19:57 PubMed PMC

Bubeník J, Kieler J, Indrová M (1986a) Local treatment with human recombinant interleukin 2 inhibits growth of MC-induced sarcomas in syngeneic mice. Folia Biol (Praha) 32:209 PubMed

Bubeník J, Kieler J, Tromholt V, Steven K, Indrová M, Toulcová A (1986b) Activation of killer cells from blood of urinary bladder carcinoma patients by short-term treatment with recombinant interleukin 2. Folia Biol (Praha) 32:183 PubMed

Bubeník J, Kieler J, Tromholt V, Indrová M, Lotzová E (1987a) Recombinant interleukin 2 inhibits growth of human tumor xenografts in congenitally athymic mice. Immunol Lett 14:325 PubMed

Bubeník J, Cinader B, Indrová M, Koh SW, Chou CT (1987b) Lymphokine-activated killer (LAK) cells: I. Age-dependent decline of LAK cell-mediated cytotoxicity. Immunol Lett 16:113 PubMed

Bubeník J, Kieler J, Tromholt V, Hermann G, Jandlová T (1988a) Defect in lectin-induced interleukin 2 production by peripheral blood lymphocytes of patients with invasive urinary bladder carcinoma. Immunol Lett 18:115 PubMed

Bubeník J, Voitenok NN, Kieler J, Prassolov VS, Chumakov PM, Bubeníková D, Šímová J, Jandlová T (1988b) Local administration of cells containing an inserted IL-2 gene and producing IL-2 inhibits growth of human tumours in nu/nu mice. Immunol Lett 19:279 PubMed

Cortesina G, De Stefani A, Giovarelli M, Baroglio MG, Cavallo GP, Jemma C, Forni G (1988) Treatment of recurrent squamous cell carcinoma of the head and neck with low doses of interleukin-2 injected perilymphatically. Cancer 62:2482 PubMed

Donohue JH, Rosenberg SA (1983) The fate of interleukin-2 after in vivo administration. J Immunol 130:2203 PubMed

Forni G, Giovarelli M, Santoni A (1985) Lymphokine-activated tumor inhibition in vivo: 1. The local administration of interleukin 2 triggers nonreactive lymphocytes from tumor-bearing mice to inhibit tumor growth. J Immunol 134:1305 PubMed

Forni G, Cavallo GP, Giovareli M, Benetton G, Jemma C, Baroglio MG, De Stefani A, Forni M, Santoni A, Modesti A, Cavallo G, Menzio P, Cortesina G (1988) Tumor immunotherapy by local injection of interleukin 2 and non-reactive lymphocytes. Progr Exp Tumor Res 32:187 PubMed

Herberman RB, Hiserodt J, Vujanovic N, Balch C, Lotzová E, Bolhuis R, Golub S, Lanier LL, Phillips JH, Riccardi C, Ritz J, Santoni A, Schmidt RE, Uchida A (1987) Lymphokine-activated cells and their progenitors in blood and spleen. Immunol Today 8:178 PubMed

Indrová M, Bubeník J (1988) Generation of LAK cells depends on the age of LAK cell precursor donors. Folia Biol (Praha) 34:48 PubMed

Maekawa R, Matsumoto M, Kitagawa T, Harada M, Sato K (1986) Effect of recombinant interleukin 2 (R-IL 2) on in vivo growth of murine myeloma X5563. Cancer Immunol Immunother 23:25 PubMed PMC

Morgan DA, Ruscetti FW, Gallo R (1976) Selective in vitro growth of T-lymphocytes from normal human bone marrow. Science 193:1007 PubMed

Mulé JJ, Yang J, Shu S, Rosenberg SA (1986) The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: Direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells. J Immunol 136:3899 PubMed

Nishimura T, Uchiyama Y, Yagi H, Hashimoto Y (1986) Administration of slowly released recombinant interleukin 2. J Immunol Methods 91:21 PubMed

Pizza G, Severini G, Menniti D, De Vinci C, Corrado F (1984) Tumour regression after intralesional injection of interleukin 2 (IL-2) in bladder cancer. Int J Cancer 34:359 PubMed

Rosenberg SA (1988) Immunotherapy of cancer using interleukin 2: current status and future prospects. Immunol Today 9:58 PubMed

Silagi S, Schaefer AE (1986) Successful immunotherapy of mouse melanoma and sarcoma with recombinant interleukin 2 and cyclophosphamide. J Biol Response Mod 5:411 PubMed

Šímová J, Bubeník J, Hausner P, Klener P, Cinader B (1987) Expression of IL-2 receptors on peripheral blood lymphocytes from young adult and aged human donors. Folia Biol (Praha) 33:282 PubMed

Šímová J, Bubeník J, Voitenok NN, Gren E (1989) Chemoimmunotherapy of MC-induced mouse sarcomas with human recombinant interleukin 2 and cyclophosphamide: age-dependent decline of the therapeutic efficacy. Folia Biol (Praha) 35:137 PubMed

Smith KA (1988) Interleukin-2: inception, impact and implications. Science 240:1169 PubMed

Vaage J (1987) Local and systemic effects during interleukin-2 therapy of mouse mammary tumors. Cancer Res 47:4296 PubMed

Vaage J (1988) Local interleukin 2 therapy of mouse mammary tumors of various immunogenicities. Cancer Res 48:2193 PubMed

Vaage J, Pauly JL, Harlos JP (1987) Influence of the administration schedule on the therapeutic effect of interleukin-2. Int J Cancer 39:530 PubMed

Yasumoto K, Miyazaki K, Nagashima A, Ishida T, Kuda T, Yano T, Sugimachi K, Nomoto K (1987) Induction of lymphokine-activated killer cells by intrapleural instillations of recombinant interleukin-2 in patients with malignant pleurisy due to lung cancer. Cancer Res 47:2184 PubMed

Yoshida S, Tanaka R, Takai N, Ono K (1988) Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors. — Cancer Res 48:5011 PubMed

Interleukin-2 gene therapy of residual EL-4 leukaemia potentiates the effect of cyclophosphamide pretreatment

Utilization of interleukin-2 gene transfer in local immunotherapy of cancer